Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04151238
Other study ID # T306/2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 17, 2020
Est. completion date May 8, 2020

Study information

Verified date November 2022
Source Turku University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Exhausting chemotherapy, adverse effects of chemotherapy and a lack of information on the benefits of physical exercise are the among the reasons for reduced physical exercise among cancer patients during chemotherapy courses. According to best current knowledge only about 10% of cancer patients in Finland are physically active during cancer treatment. In addition, only 20-30% are physically active after recovery from the treatments (Pylkkänen, 2015). There is only little awareness about the benefits of physical activity during cancer treatments. The purpose of the exercise intervention study is to increase the physical activity of patients who are on chemotherapy. The study is a pilot trial and has no control group. Internationally, exercise interventions have been studied among cancer patients on treatment for decades. The American College of Sports Medicine (ACSM) recommends that cancer patients should have 150 minutes of endurance exercise per week and at least two bouts of muscle strength exercise per week. Consequently, the exercise intervention study will have a combination of muscle power and endurance training. To reach the weekly recommended level of exercise, the cancer patients in the study will additionally have a weekly home training program containing preferentially endurance training. A literature search shows that no studies on exercise interventions during cancer treatment have been published in Finland. Thus, this thesis carries the wider implication of increasing the general knowledge on the importance of physical activity of cancer patients.


Description:

The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home. Data on training at home and other items of physical activity is recorded in a diary. Before the intervention is started, an oncologist will examine the participants condition before brisk physical activity is started. Safety is an important consideration and a nurse will examine the patients before each bout of exercise. A nurse will be present during the entire time of the exercise. A physician is always available for consultations by phone. Before the intervention starts, baseline measurements will be made in the laboratories of physical exercise in the Tyks Hospital and the Turku University of Applied Sciences. At baseline, endurance, muscle power, balance and body composition will be evaluated and recorded. Endurance will be measured with a submaximal treadmill test. Muscle power will be assessed by a dynamic elevation test, hand pressure test, the lower extremities by repeated squatting-standing and by rising to stand on the toes. Balance is measured in the specific sway platform (one leg and both legs standing). The patients will be asked to fill questionnaires on quality of life (QLQ-c30) and fatigue (FACIT-F) before and after the intervention. The patients will fill in their exercise diaries from the very moment their participation has been decided until the end of the intervention. After exercise intervention the patients also fill the feedback-questionnaire.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date May 8, 2020
Est. primary completion date April 16, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - cancer patients in the age of 18-70 - in the early phase of chemotherapy - first line chemotherapy - active way of treating cancer - solid tumor (breast cancer, prostata cancer, colon cancer and melanoma) - Finnish-speaking - z=0-1 (no aids) - capable travelling to University hospital for 8 weeks twice a week - normal or poor physical activity background Exclusion Criteria: - exercise contraindications, like severe respiratory or circulatory system disease (eg. heart attack <3) - brain or bone metastasis - heterogenous group (max 4 patients per cancer diagnose) - thrombocytopenia - leukocytopenia - immuno-oncological treatments - really "athlete patients"

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise intervention for cancer patients to increase physical activity during chemotherapy
The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.

Locations

Country Name City State
Finland Turku University hospital Turku

Sponsors (2)

Lead Sponsor Collaborator
Turku University Hospital Turku AMK Master School

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary physical activity changes in diary Does this exercise intervention model works for cancer patients to increase the amount of physical activity and to achieve the cancer patients exercise recommendations? (especially home-exercising) 0 and 8 weeks,
Primary questionnaire-feedback from cancer patients Does this exercise intervention model works for cancer patients to change the amount of physical activity? Patients subjective feedback about the first exercise group model in special health care. The questions are formed in quantitative way. 0 and 8 weeks
Secondary Quality of life questionnaire (EORTC QLQ-c30) Does the guided exercise intervention (physical activity) affect the patients quality of life during chemotherapy? The scales and single-item measures range in score from 0 to 100. High score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. The scale consists of three different part. 0 and 8 weeks
Secondary Fatigue questionnaire (FACIT-F) Does the guided exercise intervention (physical activity) affect the patients fatigue during chemotherapy? The score range: 0-52 points. The bigger points the worse fatigue or more symptoms. 0 and 8 weeks
Secondary Body composition in cancer patients general view (In-Body-device) Does exercise intervention (physical activity) cause changes in the body composition of cancer patients on chemotherapy? The device measures body mass index, fluid, fat and muscle changes. We follow up the changes in general view. 0 and 8 weeks
Secondary Endurance (submaximal treadmill test) Does exercise intervention (physical activity) cause changes in endurance of cancer patients on chemotherapy? 0 and 8 weeks
Secondary Functional muscle power test - dynamic elevation test for upper arms Does exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy? 0 and 8 weeks
Secondary Functional muscle power test - hand pressure test Does exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy? 0 and 8 weeks
Secondary Functional muscle power test - the lower extremities by repeated squatting-standing Does exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy? 0 and 8 weeks
Secondary Functional muscle power test - the lower extremities by rising to stand on the toes Does exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy? 0 and 8 weeks
Secondary Functional muscle power test - plank-test for the body Does exercise intervention (physical activity) cause changes in muscle power of cancer patients on chemotherapy? 0 and 8 weeks
Secondary Balance -tests in specific sway-platform (standing with both legs and only one leg in sway-platform) Does exercise intervention (physical activity) cause changes in the balance of cancer patients on chemotherapy? 0 and 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients